Capital International Inc. CA Acquires 33,489 Shares of Pfizer Inc. (NYSE:PFE)

Capital International Inc. CA lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 10.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 349,653 shares of the biopharmaceutical company's stock after buying an additional 33,489 shares during the period. Capital International Inc. CA's holdings in Pfizer were worth $9,276,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Retirement Wealth Solutions LLC purchased a new stake in Pfizer during the 4th quarter valued at about $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the fourth quarter worth $28,000. Noble Wealth Management PBC bought a new stake in Pfizer in the 4th quarter worth $31,000. Finally, Curio Wealth LLC bought a new position in shares of Pfizer during the fourth quarter valued at about $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on PFE shares. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group cut their price objective on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.07.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Stock Performance

PFE traded down $0.07 during midday trading on Monday, hitting $22.07. 31,814,050 shares of the company traded hands, compared to its average volume of 40,452,372. The firm has a market capitalization of $125.17 billion, a PE ratio of 15.65, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company's 50-day moving average is $24.81 and its 200 day moving average is $26.11. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the business posted $0.10 EPS. The company's revenue for the quarter was up 24.7% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.